Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Published on February 24, 2022

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Continue reading on website
Other news

2 Tech Stocks to Buy on Weakness

February 24, 2022
It’s been a turbulent start to the year for Tech, with the Nasdaq 100 Index (QQQ) sliding more than 18% from its highs and the Nasdaq Composite down more than...

'Boxing and Fitness Without a Doubt Saved My Life': Floyd Mayweather Jr. Saw the Impact that Channeling Community and Hard Work Through Fitness Had on His Life. Now He's Paying It Forward.

February 24, 2022
Mayweather Boxing + Fitness is set for exponential expansion over the next few years.